Advertisement
Advertisement
CRDF
Cardiff Oncology, Inc. Common Stock
1.26
USDSponsored
+0.01
+0.80%
Jun 24, 16:00 UTC -4
Closed
Pre-Market
1.30
+0.04
+3.17%
CRDF Earnings Reports
Positive Surprise Ratio
CRDF beat 24 of 41 last estimates.
59%
Next Report
Date of Next Report
Jul 27, 2026
Estimate for Q2 26 (Revenue/ EPS)
$72.12K
/-$0.16
Implied change from Q1 26 (Revenue/ EPS)
+75.91%
/-11.11%
Implied change from Q2 25 (Revenue/ EPS)
-40.39%
/-23.81%
Cardiff Oncology, Inc. Common Stock earnings per share and revenue
On May 14, 2026, CRDF reported earnings of -0.18 USD per share (EPS) for Q1 26, missing the estimate of -0.13 USD, resulting in a -31.10% surprise. Revenue reached 41.00 thousand, compared to an expected 86.70 thousand, with a -52.71% difference. The market reacted with a -1.16% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 72.12 thousand USD, implying an decrease of -11.11% EPS, and increase of 75.91% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Grace Therapeutics, Inc. Common Stock
Report Date
Jun 18, 2026 For Q4 26
Estimate
-$0.23
Actual
-$0.06
Surprise
+74.42%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were Cardiff Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Cardiff Oncology, Inc. Common Stock reported EPS of -$0.18, missing estimates by -31.1%, and revenue of $41.00K, -52.71% below expectations.
How did the market react to Cardiff Oncology, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -1.16%, changed from $1.73 before the earnings release to $1.71 the day after.
When is Cardiff Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jul 27, 2026.
What are the forecasts for Cardiff Oncology, Inc. Common Stock's next earnings report?
Based on 8
analysts, Cardiff Oncology, Inc. Common Stock is expected to report EPS of -$0.16 and revenue of $72.12K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement